RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
暂无分享,去创建一个
G. Salles | P. Zinzani | M. Winderlich | B. Feinberg | S. Ambarkhane | G. Nowakowski | A. Barbui | Thomas D. Rodgers | S. Tillmanns | N. Fowler | G. Fingerle-Rowson | S. Parche | D. Marino | E. Meli | M. Frezzato | C. Castellino